Working… Menu

Optimal Dosage of Caspofungin in Critically Ill Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01994096
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : October 30, 2015
Information provided by (Responsible Party):
JWC Alffenaar, University Medical Center Groningen

Brief Summary:

Intensive care unit (ICU) patients are especially at risk for invasive candidiasis due to the presence of risk factors. It is known that in critically ill patients, alterations in function of various organs and body systems can influence the pharmacokinetics and hence the plasma concentration of a drug. A study of caspofungin in ICU patients has found a high inter- and intra-individual variability in caspofungin concentration. Factors that caused subtherapeutic caspofungin plasma concentrations were body weight > 75 kg and hypoalbuminemia. Furthermore, an efficacy study showed a lower response rate for caspofungin among patients with a higher disease severity score.

As a result of the altered pharmacokinetics, under- or over-exposure of caspofungin can occur in critically ill patients and an adjusted dosage might be necessary in these patients.

Condition or disease Intervention/treatment Phase
Critically Ill Suspected Invasive Candidiasis Drug: Caspofungin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis
Study Start Date : November 2013
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Yeast Infections

Arm Intervention/treatment
Experimental: Caspofungin
1 arm, dose adjustment of caspofungin when exposure is inadequate
Drug: Caspofungin

Primary Outcome Measures :
  1. The optimal dosage of caspofungin in relation to adequate exposure (measured as AUC) in critically ill patients. [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Pharmacokinetic parameters of caspofungin in critically ill patients. [ Time Frame: 3 days ]
  2. Correlation of pharmacokinetic parameters and the plasma concentration of caspofungin with disease severity scores. [ Time Frame: 3 days ]
  3. Correlation of the plasma concentration of caspofungin with candida eradication. [ Time Frame: 28 days ]
  4. Correlation of the plasma concentration of caspofungin with inflammation parameters. [ Time Frame: 3 days ]
  5. AUC/MIC ratio and highest observed plasma concentration (Cmax)/MIC ratio. [ Time Frame: 7 days ]
  6. Constructing a pharmacokinetic model of caspofungin in critically ill patients. [ Time Frame: 28 days ]
  7. Drug-related adverse events of caspofungin. [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Treatment with caspofungin.
  • Admission to an ICU.
  • Age ≥ 18 years.
  • Suspected invasive candidiasis, established by the physician.

Exclusion Criteria:

  • Blood sampling by central venous catheter or peripheral cannula not possible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01994096

Layout table for location information
University Medical Centre Groningen
Groningen, Netherlands, 9700 RB
Sponsors and Collaborators
University Medical Center Groningen
Layout table for investigator information
Principal Investigator: Jan-Willem Alffenaar, PharmD, PhD University Medical Center Groningen
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: JWC Alffenaar, PharmD, PhD, University Medical Center Groningen Identifier: NCT01994096    
Other Study ID Numbers: NL41676.042.12
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: October 30, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Candidiasis, Invasive
Critical Illness
Disease Attributes
Pathologic Processes
Invasive Fungal Infections
Antifungal Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action